AU737634B2 - Pharmaceutical composition for gastric residence - Google Patents

Pharmaceutical composition for gastric residence Download PDF

Info

Publication number
AU737634B2
AU737634B2 AU73416/98A AU7341698A AU737634B2 AU 737634 B2 AU737634 B2 AU 737634B2 AU 73416/98 A AU73416/98 A AU 73416/98A AU 7341698 A AU7341698 A AU 7341698A AU 737634 B2 AU737634 B2 AU 737634B2
Authority
AU
Australia
Prior art keywords
composition according
carbon dioxide
benzamide
dioxide generator
amisulpride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU73416/98A
Other languages
English (en)
Other versions
AU7341698A (en
Inventor
Jerome Besse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU7341698A publication Critical patent/AU7341698A/en
Application granted granted Critical
Publication of AU737634B2 publication Critical patent/AU737634B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU73416/98A 1997-04-18 1998-04-15 Pharmaceutical composition for gastric residence Ceased AU737634B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR97/04803 1997-04-18
FR9704803A FR2762213B1 (fr) 1997-04-18 1997-04-18 Composition pharmaceutique a retention gastrique
PCT/FR1998/000755 WO1998047506A1 (fr) 1997-04-18 1998-04-15 Composition pharmaceutique a residence gastrique

Publications (2)

Publication Number Publication Date
AU7341698A AU7341698A (en) 1998-11-13
AU737634B2 true AU737634B2 (en) 2001-08-23

Family

ID=9506077

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73416/98A Ceased AU737634B2 (en) 1997-04-18 1998-04-15 Pharmaceutical composition for gastric residence

Country Status (19)

Country Link
EP (1) EP0983065A1 (hu)
JP (1) JP2001523241A (hu)
KR (1) KR20010006353A (hu)
CN (1) CN1252720A (hu)
AR (1) AR015586A1 (hu)
AU (1) AU737634B2 (hu)
CA (1) CA2286081A1 (hu)
FR (1) FR2762213B1 (hu)
HU (1) HUP0002455A3 (hu)
IL (1) IL131995A0 (hu)
JO (1) JO2017B1 (hu)
MA (1) MA26482A1 (hu)
NO (1) NO995039L (hu)
NZ (1) NZ500288A (hu)
PE (1) PE68199A1 (hu)
PL (1) PL336273A1 (hu)
TN (1) TNSN98049A1 (hu)
WO (1) WO1998047506A1 (hu)
ZA (1) ZA983258B (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987230B2 (en) 2012-10-12 2018-06-05 Omya International Ag Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
WO2009157711A2 (ko) * 2008-06-24 2009-12-30 Park Eun-Seok 위장체류형 다공성 정제 및 그의 제조 방법
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62178518A (ja) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk 新規持続性スルピリド錠剤
WO1987006130A1 (fr) * 1986-04-16 1987-10-22 Laboratoires Delagrange Comprimes a matrice
US5137730A (en) * 1990-04-23 1992-08-11 E. R. Squibb & Sons, Inc. Tablet composition and method for problem pharmaceutical materials using citric acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
FR2554718B1 (fr) * 1983-11-14 1986-04-04 Ethypharm Sa Nouvelles formes galeniques du sulpiride utilisables par voie orale
FR2556964A1 (fr) * 1983-12-23 1985-06-28 Ile De France Nouvelles formes galeniques du sulpiride utilisables par voie orale

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62178518A (ja) * 1986-01-30 1987-08-05 Toho Yakuhin Kogyo Kk 新規持続性スルピリド錠剤
WO1987006130A1 (fr) * 1986-04-16 1987-10-22 Laboratoires Delagrange Comprimes a matrice
US5137730A (en) * 1990-04-23 1992-08-11 E. R. Squibb & Sons, Inc. Tablet composition and method for problem pharmaceutical materials using citric acid

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987230B2 (en) 2012-10-12 2018-06-05 Omya International Ag Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate
US9993428B2 (en) 2012-10-12 2018-06-12 Omya International Ag Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate

Also Published As

Publication number Publication date
EP0983065A1 (fr) 2000-03-08
WO1998047506A1 (fr) 1998-10-29
FR2762213B1 (fr) 1999-05-14
JP2001523241A (ja) 2001-11-20
ZA983258B (en) 1998-10-19
KR20010006353A (ko) 2001-01-26
HUP0002455A2 (hu) 2000-12-28
NZ500288A (en) 2001-03-30
JO2017B1 (en) 1999-05-15
NO995039D0 (no) 1999-10-15
TNSN98049A1 (fr) 2005-03-15
AR015586A1 (es) 2001-05-16
AU7341698A (en) 1998-11-13
MA26482A1 (fr) 2004-12-20
CN1252720A (zh) 2000-05-10
PL336273A1 (en) 2000-06-19
IL131995A0 (en) 2001-03-19
FR2762213A1 (fr) 1998-10-23
HUP0002455A3 (en) 2001-01-29
NO995039L (no) 1999-12-17
PE68199A1 (es) 1999-07-15
CA2286081A1 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
US20220133778A1 (en) Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2453117C (en) Oral dosage forms comprising a benzimidazole and buffer
US6699885B2 (en) Substituted benzimidazole dosage forms and methods of using same
CA2609627C (en) Pharmaceutical formulations useful for inhibiting acid secretion
US20120142737A1 (en) Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
AU737634B2 (en) Pharmaceutical composition for gastric residence
AU2002330863A1 (en) Novel substituted benzimidazole dosage forms and method of using same
JP2002529407A (ja) Ｌ−ｄｏｐａエチルエステル含有分散性組成物
AU1451201A (en) Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
JP2003519656A (ja) 新規な置換ベンズイミダゾール投与形態およびそれらの使用方法
JP2002527464A (ja) 胃滞留性の制御放出医薬組成物
BRPI0015061B1 (pt) comprimido revestido tendo alta dosagem de cloridrato de sevelamer
US5213806A (en) Pharmaceutical composition comprising calcium polycarbophil
JP3110794B2 (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
US20010046473A1 (en) Gastric-retained pharmaceutical composition and method for its use
JP5721093B2 (ja) 崩壊錠
EP1353624B1 (en) Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
CZ364099A3 (cs) Farmaceutický prostředek vhodný pro zadržení v žaludku
AU2011265561B2 (en) Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005331781C1 (en) Pharmaceutical formulations useful for inhibiting acid secretion
AU2003214858A1 (en) Novel substituted benzimidazole dosage forms and method of using same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired